ArticleThoracic cancer2016
Prognostic significance of RelB overexpression in non-small cell lung cancer patients.
Article in Thoracic cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis.PloS one · 2018Pooled it
- Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dual-edged mechanisms of α-tomatine in hepatocellular carcinoma by suppression of Wnt/β-catenin signaling versus RelB-Driven resistance in tumor therapy.Frontiers in pharmacology · 2025Article
- Gene expression alterations in hypoxic A549 lung cancer cell line.Biomedical reports · 2024Article
- Review
- Human Papillomavirus in Non-Small Cell Lung Carcinoma: Assessing Virus Presence in Tumor and Normal Tissues and Its Clinical Relevance.Microorganisms · 2023Article
- Xprediction: Explainable EGFR-TKIs response prediction based on drug sensitivity specific gene networks.PloS one · 2022Article
- Targeting NF-κB mediated cell signaling pathway and inflammatory mediators by 1,2-diazole in A549 cellsBiotechnology reports (Amsterdam, Netherlands) · 2021Article
- Article
- Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma.Molecular therapy. Nucleic acids · 2019Article
- IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.Cell cycle (Georgetown, Tex.) · 2019Article
- Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome.Journal of cancer research and clinical oncology · 2019Article
- Expression Of Intracellular Components of the NF-κB Alternative Pathway (NF-κB2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients.Scientific reports · 2019Article
- Review
- Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients.Journal of Cancer · 2019Article
- Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.Cells · 2018Review
- Exopolysaccharides from a Codonopsis pilosula endophyte activate macrophages and inhibit cancer cell proliferation and migration.Thoracic cancer · 2018Article
- p52 expression enhances lung cancer progression.Scientific reports · 2018Article
- Co-expression of NF-κB-p65 and phosphorylated NF-κB-p105 is associated with poor prognosis in surgically resectable non-small cell lung cancer.Journal of cellular and molecular medicine · 2018Article
- The nuclear transcription factor RelB functions as an oncogene in human lung adenocarcinoma SPC-A1 cells.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a major public health issue in most countries, including China. The expression of RelB is associated with poor prognosis in diverse cancers. However, whether RelB expression could be an indicator of poor prognosis in non-small cell lung cancer (NSCLC) is still unclear.
methodsThe expression of RelB in NSCLC tumor tissue and adjacent non-neoplastic tissues were examined by immunohistochemistry. Chi-square or two-tailed Fisher's exact tests were used to analyze possible associations between qualitative clinicopathological variables and RelB expression. Kaplan-Meier analysis and a Cox regression model were employed to determine independent prognostic factors.
resultsThe expression of RelB was increased in tumor tissue compared with adjacent non-neoplastic tissue in NSCLC patients. High RelB expression was significantly correlated with degree of differentiation (P = 0.023), depth of tumor invasion (P < 0.001), lymph node metastasis (P = 0.017), distant metastases (P = 0.004), and tumor node metastasis stage (P < 0.001) in patients with NSCLC. NSCLC patients with high RelB expression had significantly shorter overall survival than those with low RelB expression (P < 0.001). Our results indicate that high RelB expression is an independent prognostic factor for patients with NSCLC (P < 0.001).
conclusionsHigh RelB expression could provide a basis for judgment of prognosis in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.